Logo image of INDV

INDIVIOR PLC (INDV) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:INDV - GB00BN4HT335 - Common Stock

35.44 USD
-0.07 (-0.2%)
Last: 1/9/2026, 8:00:01 PM
35.0958 USD
-0.34 (-0.97%)
After Hours: 1/9/2026, 8:00:01 PM

INDV Key Statistics, Chart & Performance

Key Statistics
Market Cap4.42B
Revenue(TTM)1.18B
Net Income(TTM)122.00M
Shares124.85M
Float120.03M
52 Week High38
52 Week Low7.62
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)1.96
PE18.08
Fwd PE12.13
Earnings (Next)02-18 2026-02-18/amc
IPO2014-12-24
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


INDV short term performance overview.The bars show the price performance of INDV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

INDV long term performance overview.The bars show the price performance of INDV in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of INDV is 35.44 USD. In the past month the price decreased by -0.03%. In the past year, price increased by 199.07%.

INDIVIOR PLC / INDV Daily stock chart

INDV Latest News, Press Relases and Analysis

INDV Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.37 1.01T
JNJ JOHNSON & JOHNSON 19.69 492.44B
MRK MERCK & CO. INC. 12.55 274.34B
PFE PFIZER INC 7.96 144.87B
BMY BRISTOL-MYERS SQUIBB CO 8.52 113.72B
ZTS ZOETIS INC 20.06 56.04B
RPRX ROYALTY PHARMA PLC- CL A 9.77 23.19B
VTRS VIATRIS INC 5.48 14.70B
ELAN ELANCO ANIMAL HEALTH INC 24.45 11.66B
AXSM AXSOME THERAPEUTICS INC N/A 8.54B
BLTE BELITE BIO INC - ADR N/A 5.53B
CRNX CRINETICS PHARMACEUTICALS IN N/A 5.05B

About INDV

Company Profile

INDV logo image Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. The company is headquartered in Slough, Berkshire and currently employs 1,030 full-time employees. The company went IPO on 2014-12-24. The firm provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The firm sells its products in the United States and in other selected areas of the world.

Company Info

INDIVIOR PLC

234 Bath Road

SLOUGH BERKSHIRE GB

Employees: 1030

INDV Company Website

INDV Investor Relations

Phone: 448043791090

INDIVIOR PLC / INDV FAQ

What does INDV do?

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. The company is headquartered in Slough, Berkshire and currently employs 1,030 full-time employees. The company went IPO on 2014-12-24. The firm provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The firm sells its products in the United States and in other selected areas of the world.


What is the stock price of INDIVIOR PLC today?

The current stock price of INDV is 35.44 USD. The price decreased by -0.2% in the last trading session.


Does INDV stock pay dividends?

INDV does not pay a dividend.


How is the ChartMill rating for INDIVIOR PLC?

INDV has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Can you provide the market cap for INDIVIOR PLC?

INDIVIOR PLC (INDV) has a market capitalization of 4.42B USD. This makes INDV a Mid Cap stock.


Can you provide the upcoming earnings date for INDIVIOR PLC?

INDIVIOR PLC (INDV) will report earnings on 2026-02-18, after the market close.


Can you provide the ownership details for INDV stock?

You can find the ownership structure of INDIVIOR PLC (INDV) on the Ownership tab.


INDV Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to INDV. When comparing the yearly performance of all stocks, INDV is one of the better performing stocks in the market, outperforming 98% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

INDV Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to INDV. INDV scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INDV Financial Highlights

Over the last trailing twelve months INDV reported a non-GAAP Earnings per Share(EPS) of 1.96. The EPS increased by 256.36% compared to the year before.


Industry RankSector Rank
PM (TTM) 10.34%
ROA 8.62%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%33.33%
Sales Q2Q%2.28%
EPS 1Y (TTM)256.36%
Revenue 1Y (TTM)-0.25%

INDV Forecast & Estimates

13 analysts have analysed INDV and the average price target is 38.61 USD. This implies a price increase of 8.96% is expected in the next year compared to the current price of 35.44.

For the next year, analysts expect an EPS growth of 438.48% and a revenue growth 2.65% for INDV


Analysts
Analysts84.62
Price Target38.61 (8.94%)
EPS Next Y438.48%
Revenue Next Year2.65%

INDV Ownership

Ownership
Inst Owners92.33%
Ins Owners3.78%
Short Float %5.46%
Short Ratio2.42